Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients

被引：0

作者：

Genovese, Mark C. ^{[1
]}

Fay, Jon ^{[2
]}

Parrino, Janie ^{[2
]}

Beyer, Doris ^{[3
]}

Iglesias-Rodriguez, Melitza ^{[4
]}

Graham, Neil ^{[2
]}

Boddy, Alex ^{[3
]}

Simon, J-Abraham ^{[5
]}

Martincova, Renata ^{[6
]}

Burmester, Gerd R. ^{[7
]}

机构：

[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[3] Sanofi Genzyme, Bridgewater, NJ USA

[4] Sanofi Genzyme, Cambridge, MA USA

[5] Kohler & Milstein Res, Yucatan, Mexico

[6] Sanofi Genzyme, Prague, Czech Republic

[7] Charite Univ Med Berlin, Berlin, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1631

引用

页数：2

共 50 条

[1] Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
Genovese, Mark
Fay, Jonathan
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
van Hoogstraten, Hubert
Graham, Neil
Boddy, Alex
Simon, Abraham
Martincova, Renata
Burmester, Gerd
Fiore, Stefano
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 895 - 896
[2] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Genovese, M. C.
Fay, J.
Beyer, D.
Iglesias-Rodriguez, M.
Simon, A.
Martincova, R.
Burmester, G. R.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
[3] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Genovese, M. C.
Fay, J.
Parrino, J.
Garg, A.
Van Hoogstraten, H.
Boddy, A.
Martincova, R.
Graham, N.
Simon, J.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 515 - 516
[4] Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients
Burmester, Gerd
Garg, Anju
van Hoogstraten, Hubert
Graham, Neil
Boddy, Alex
Parrino, Janie
Genovese, Mark C.
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[5] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Burmester, Gerd R.
Garg, Anju
Van Hoogstraten, Hubert
Graham, Neil
Boddy, Alexander
Parrino, Janie
Genovese, Mark C.
INTERNAL MEDICINE JOURNAL, 2016, 46 : 40 - 41
[6] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS
Fleischmann, R.
Hrycaj, P.
van Hoogstraten, H.
Mangan, E. K.
Lin, Y.
Jayawardena, S.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 853 - 853
[7] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Martincova, Renata
Burmester, Gerd R.
RHEUMATOLOGY, 2017, 56 : 139 - 139
[8] Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Fleischmann, Roy
Selmi, Carlo
Gonzalez-Gay, Miguel Angel
van Hoogstraten, Hubert
Hagino, Owen
Rajput, Tejasweeni
St John, Gregory
Buttgereit, Frank
Genovese, Mark
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[9] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE 3 MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)
Burmester, G. R.
Fiore, S.
Hu, C-C
van Hoogstraten, H.
Lee, Bong E.
Genovese, M. C.
INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 21
[10] GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING SARILUMAB: RESULTS FROM THE OPEN LABEL EXTEND STUDY
Fleischmann, Roy
Selmi, Carlo
Angel Gonzalez-Gay, Miguel
van Hoogstraten, Hubert
Hagino, Owen
Rajput, Tejasweeni
St John, Gregory
Buttgereit, Frank
Genovese, Mark C.
RHEUMATOLOGY, 2020, 59 : 108 - 108

← 1 2 3 4 5 →